Daiichi Sankyo Company has dosed the first patient in a Phase ll trial evaluating the efficacy and safety of DS-8201 for the treatment of patients with unresectable and/or metastatic non-squamous HER2-overexpressing or HER2-mutated non-small cell lung cancer (NSCLC) that has progressed after one or more prior therapies.

The global, multicentre, open-label, two-cohort trial includes two cohorts, one and two.

The cohort one will enrol nearly 40 patients with HER2-overexpressing (defined as IHC 3+ or IHC 2+), unresectable and/or metastatic non-squamous NSCLC, while the cohort two will include about 40 patients with HER2-mutated, unresectable and/or metastatic non-squamous NSCLC.

The trial’s primary endpoint is to achieve an objective response rate.

Its key secondary endpoints are efficacy, safety, and pharmacokinetic endpoints. Exploratory efficacy endpoints of the trial include time to respond, in addition to biomarker endpoints for mechanisms of response and resistance.

“There is renewed interest in exploring alterations in the HER2 pathway as treatment targets for NSCLC and clinical research suggests a potential role for a HER2-targeting ADC agent.”

Around 80 patients are scheduled to be enrolled in the trial at 20 sites in North America, Japan, and Europe.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Daiichi Sankyo Oncology Research and Development Global Team Leader DS-8201 vice-president Gilles Gallant said: “There is renewed interest in exploring alterations in the HER2 pathway as treatment targets for NSCLC and clinical research suggests a potential role for a HER2-targeting ADC agent.

“DS-8201 is specifically designed to target and deliver chemotherapy inside HER2-expressing cancer cells, and we are advancing it to Phase ll in non-small cell lung cancer as part of our broad programme in multiple types of HER2-expressing tumours.”

According to World Health Organization’s Cancer Fact Sheet 2017 and other research, lung cancer is estimated to be the most common cancer in the world and the major cause of cancer deaths.

They have also estimated that about 1.8 million new cases of lung cancer were reported globally in 2012 and nearly 1.69 million deaths occurred globally due to lung cancer in 2015.